Displacement of submacular hemorrhage associated with age-related macular degeneration using vitrectomy and submacular tPA injection followed by intravitreal ranibizumab

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 637-642

  Sandhu, Sukhpal Singh ^a,b   Manvikar, Sridhar ^a   Steel, David Henry William ^a  

^a SUNDERLAND EYE INFIRMARY   (United Kingdom)

^b CENTRE FOR EYE RESEARCH AUSTRALIA   (Australia)

Author keywords

Neovascular age related macular degeneration; Ranibizumab; Submacular hemorrhage; Tissue plasminogen activator; Vitrectomy

Indexed keywords

RANIBIZUMAB; TISSUE PLASMINOGEN ACTIVATOR;

AGE; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; DRUG ADMINISTRATION ROUTE; FLUID AIR EXCHANGE; GAS EXCHANGE; HAND MOVEMENT; HUMAN; LIGHT; PIGMENT EPITHELIUM; POSTOPERATIVE PERIOD; RECURRENT DISEASE; RETINA FOVEA; RETINA FOVEA DEHISCENCE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; RETINOTOMY; RETROSPECTIVE STUDY; SUBRETINAL DRUG ADMINISTRATION; SYMPTOM; VISION; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS HEMORRHAGE;

EID: 77956106818     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: None     Document Type: Article

References (45)

1. Avery R, Fekrat S, Hawkins B, et al. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina. 1996;16:183-189.
2. Bennett SR, Folk JC, Blodi CF, et al. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol. 1990;109:33-37.
3. Scupola A, Coscos G, Soubrane G, et al. Natural history of macular subretinal hemorrhage in age-related macular degeneration. Ophthalmologica. 1999;213:97-102.
4. Chen WL, Liu JH, Lee FL. Natural course of submacular hemorrhage. Zhonghua Yi Xue Za Zhi Taipei. 1999;62(5):268-277.
5. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol. 1982;94:762-773.
6. Toth C, Morse L, Hjelmeland L, et al. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol. 1991;109:723-729.
7. Brown DM, Kaiser PK, Michels M, et al. ANCHOR study group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
8. Rosenfield PJ, Brown DM, Heier JS, et al. MARINA study group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
9. National Institute for Health and Clinical Excellence: Pegaptanib and ranibizumab for the treatment of age-related macular degeneration. Available from: http://guidance.nice.org.uk/TA155. Accessed Sep 25, 2009.
10. Bressler NM, Bressler SB, Childs AL, et al. Submacular Surgery Trials (SST) Research Group: surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report no. 13. Ophthalmology. 2004;111:1993-2006.
11. Heriot W. Intravitreal gas and rtPA: an outpatient procedure for subretinal hemorrhage. Vail Vitrectomy Meeting 1996: 10-15 March, Vail, Colorado.
12. Hesse L, Schmidt J, Kroll P. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol. 1999;237(4):273-277.
13. Hassan AS, Johnson MW, Schneiderman TE, et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology. 1999;106(10): 1900-1906; discussion 1906-1907.
14. Lincoff H, Kreissig I. Intravitreal injection of tissue plasminogen activator and gas in subretinal hemorrhage caused by age-related macular degeneration. Retina. 2001;21:191.
15. Schulze SD, Hesse L. Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome. Graefes Arch Clin Exp Ophthalmol. 2002;240:717-720.
16. Krepler K, Kruger A, Tittl M, et al. Intravitreal injection of tissue plasminogen activator and gas in subretinal hemorrhage caused by age-related macular degeneration. Retina. 2000;20(3):251-256.
17. Hattenbach LO, Klais C, Koch FH, et al. Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology. 2001;108(8):1485-1492.
18. Haupert CL, McCuen BW, Jaffe GJ, et al. Pars plana vitrectomy, subretinal injection of tissue plasminogen activator, and fluid-gas exchange for displacement of thick submacular hemorrhage in age-related macular degeneration. Am J Ophthalmol. 2001;131(2):208-215.
19. Olivier S, Chow DR, Packo KH, et al. Subretinal recombinant tissue plasminogen activator injection and pneumatic displacement of thick submacular hemorrhage in age-related macular degeneration. Ophthalmology. 2004;111(6):1201-1208.
20. Meyer CH, Scholl HP, Eter N, et al. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol Scand. 2008;86(5):490-494.
21. Sacu S, Stifter E, Vécsei-Marlovits PV, et al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye. 2009;23(6):1404-1410.
22. Hasler PW, La Cour M, Villumsen J. Pnuematic displacement and intravitreal bevacizumab in the management of subretinal haemorrhage caused by choroidal neovascularization. Acta Ophthalmol Scand. 2007;85:577-578.
23. The Royal College of Ophthalmologists. Ranibizumab: the clinician's guide to commencing, continuing and discontinuing treatment. Available from: http://www.rcophth.ac.uk/docs/scientific/Ranibizumab_June_2008.pdf. Accessed on Sep 25, 2009.
24. Poliner LS, Oik RJ, Burgess D, et al. Natural history of retinal pigment epithelial detachments in age-related macular degeneration. Ophthalmology. 1986;93(5):543-551.
25. Baeteman C, Hoffart L, Galland F, et al. Subretinal hemorrhage after intravitreal injection of anti-VEGF for age-related macular degeneration: a retrospective study. J Fr Ophtalmol. 2009;32(5):309-313.
26. Goverdhan SV, Lochhead J. Submacular haemorrhages after intravitreal bevacizumab for large occult choroidal neovascularisation in age-related macular degeneration. Br J Ophthalmol. 2009;92(2):210-212.
27. Lincoff H, Kreissig I, Stopa M, Uram D. A 40 degrees gaze down position for pneumatic displacement of submacular hemorrhage: clinical application and results. Retina. 2008;28(1):56-59.
28. Kamei M, Misono K, Lewis H. A study of the ability of tissue plasminogen activator to diffuse into the subretinal space after intravitreal injection in rabbits. Am J Ophthalmol. 1999;128(6):739-746.
29. Lewis H. Intraoperative fibrinolysis of submacular hemorrhage with tissue plasminogen activator and surgical drainage. Am J Ophthalmol. 1994;118(5):559-568.
30. Hillenkamp J, Surguch V, Framme C, et al. Management of submacular hemorrhage with intravitreal versus subretinal injection of recombinant tissue plasminogen activator. Graefes Arch Clin Exp Ophthalmol. Epub 2009 Aug 11.
31. Lee SJ, Lee CS, Koh HJ. Posterior vitreomacular adhesion and risk of exudative age-related macular degeneration: paired eye study. Am J Ophthalmol. 2009;147(4):621.e1-626.e1.
32. Mojana F, Cheng L, Bartsch DU, et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol. 2008;146(2):218-227.
33. Stefánsson E. Physiology of vitreous surgery. Graefes Arch Clin Exp Ophthalmol. 2009;247(2):147-163.
34. Williamson TH, Grewal J, Gupta B, et al. Measurement of PO2 during vitrectomy for central retinal vein occlusion, a pilot study. Graefes Arch Clin Exp Ophthalmol. 2009;247(8):1019-1023.
35. Chin HS, Park TS, Moon YS, Oh JH. Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina. 2005;25(5):556-560.
36. Doft BH, Weiskopf J, Nilsson-Ehle I, Wingard LB Jr. Amphotericin clearance in vitrectomized versus nonvitrectomized eyes. Ophthalmology. 1985;92(11):1601-1605.
37. Treumer F, Klatt C, Roider J, Hillenkamp J. Subretinal co-application of recombinant tissue plasminogen activator and bevacizumab for neovascular age-related macular degeneration with submacular hemorrhage. Br J Ophthalmol. Epub 2009 Nov 27.
38. Krishnan R, Goverdhan S, Lochhead J. Submacular haemorrhage after intravitreal bevacizumab compared with intravitreal ranibizumab in large occult choroidal neovascularization. Clin Experiment Ophthalmol. 2009;37(4):384-388.
39. Karagiannis DA, Mitropoulos P, Ladas ID. Large subretinal haemorrhage following change from intravitreal bevacizumab to ranibizumab. Ophthalmologica. 2009;223(4):279-282.
40. Chen CY, Hooper C, Chiu D, et al. Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas. Retina. 2007;27(3):321-328.
41. Vote BJ, Buttery R, Polkinhorne PJ. Endophthalmitis after intravitreal injection of frozen prepared tissue activator (tPA) for pneumatic displacement of submacular hemorrhage. Retina. 2000;20(3):251-256.
42. Mali RS, Cheng M, Chintala SK. Plasminogen activators promote excitotoxicity-induced retinal damage. FASEB J. 2005;19(10): 1280-1289.
43. Chen SN, Yang TC, Ho CL, et al. Retinal toxicity of intravitreal tissue plasminogen activator: case report and literature review. Ophthalmology. 2003;110(4):704-708.
44. Soliman W, Lund-Anderson H, Larsen M. Resolution of subretinal haemorrhage and fluid after bevacizumab in aggressive peripapillary subretinal neovascularization. Acta Ophthalmol Scand. 2006;84:707-708.
45. Stifter E, Michels S, Prager F, et al. Intravitreal bevacizumab therapy for neovascular age-related macular degeneration with large submacular hemorrhage. Am J Ophthalmol. 2007;144(6):886-892.